Sage Therapeutics Inc Expected To Post A Loss Of 95 Cents A Share: Earnings Preview

Sage Therapeutics

25/07/2025 12:36

SAGE Therapeutics Inc SAGE.OQ SAGE.O is expected to  show a rise in quarterly revenue when it reports  results on July 29 (estimated) for the period ending June 30 2025

The Cambridge Massachusetts-based  company is expected to report a 93.7% increase in revenue to $16.764 million from $8.65 million a year ago, according to the mean estimate from 15 analysts, based on LSEG data.

​LSEG's mean analyst estimate for SAGE Therapeutics Inc is for a loss of 95 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 14 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for SAGE Therapeutics Inc is $8.50, about 3.1% below its last closing price of $8.76

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-1.00
-1.00
-1.01
Missed
-1.5
Dec. 31 2025
-1.52
-1.51
-1.56
Missed
-3.6
Sep. 30 2024
-1.53
-1.53
-1.53
Met
0.2​
Jun. 30 2024
-1.70
-1.66
-1.70
Missed
-2.5
​​Mar. 31 2024
-1.64
-1.65
-1.80
Missed
-9.3
Dec. 31 2023
-1.65
-1.28
-1.80
Missed
-40.9​
Sep. 30 2023
-2.76
-2.73
-3.37
Missed
-23.4
Jun. 30 2023
-2.56
-2.55
-2.68
Missed
-4.9

This summary was machine generated July 25 at 11:36 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)